Skip to main content

Advertisement

Table 1 Main characteristics of the eligible studies included in the meta-analysis

From: Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis

Author Year Country Patients number Age (years) FIGO Stage Tumor Grade Tumor type cut-off value (× 109/L) Incidence of thrombocytosis (%) Follow-up time (month) Primary Outcome NOS
Abu-Zaid [24] 2017 Saudi Arabia 162 59 I–IV 1–3 endometrioid 400 8.6 NR OS, DFS 6
Andersen [27] 2017 Denmark 218 18–80 I–IV 1–3 mixed 400 11.5 NR OS, DSS 6
Njølstad [28] 2013 Norway 512 28–93 I–IV 1–3 mixed 390 12.3 55(0–97) DFS 6
Kizer [22] 2015 USA 318 62 I–IV 1–3 mixed 400 16.7 NR DFS, DSS 6
Nakamura [23] 2016 Japan 108 60 I–IV 1–3 mixed 350 11.02 NR OS, PFS 6
Takahashi [26] 2017 Japan 508 58 I–IV 1–3 mixed 400 7 NR OS 6
Heng [20] 2014 Thailand 238 28–88 I–IV 1–3 mixed 400 18.1 59.6(1–98) OS, DFS 7
Matsuo [19] 2013 USA 516 52 I–IV 1–3 mixed 400 15.1 43.7 OS, DFS 8
Gorelick [18] 2009 USA 77 65 I–IV 1–3 mixed 400 18.2 NR OS 6
Lerner [17] 2007 USA 68 NR III-IV NR serous 400 12 NR OS 6
Moeini [25] 2017 USA 714 53.1 I–IV 1–3 mixed 400 24.8 28.8 OS, DFS 8
  1. Abbreviations: NOS Newcastle Ottawa Scale, NR not reported, FIGO International Federation of Gynecology and Obstetrics, OS overall survival, PFS progression-free survival, DFS disease-free survival, DSS disease-specific survival